Thymosin Alpha-1

Thymosin alpha-1 is a small 28-amino-acid peptide with an acetylated N-terminus, a molecule the thymus gland naturally produces as part of the signaling system it uses to mature and activate T cells. It was first isolated and sequenced in 1977 by Allan Goldstein and colleagues, building on work from the 1960s at the Albert Einstein College of Medicine, where researchers were fractionating a crude thymus extract called thymosin fraction 5. Thymosin alpha-1 turned out to be one of the most active components of that mixture. It should not be confused with thymosin beta-4, the parent of TB-500, which came from the same original extract but works on actin and tissue repair rather than immune regulation. The synthetic version is called thymalfasin, and it entered clinical use abroad under the brand name Zadaxin, where it has been studied and marketed for decades.

People look into thymosin alpha-1 mainly for immune support, particularly in situations where the immune system is underperforming rather than for a quick lift when already healthy. The clearest clinical use case worldwide is chronic hepatitis B, usually alongside standard antiviral drugs, and it has also been studied as a vaccine enhancer, most notably improving influenza antibody responses in older adults. It draws interest for age-related immune decline, sometimes called immunosenescence, since thymic output falls sharply with age and endogenous production drops during serious illness. Other reported reasons include postviral fatigue and long COVID, where T cells appear exhausted, recurrent infections without an obvious cause, and use as an adjunct during cancer treatment to support an immune system suppressed by chemotherapy or radiation. Commentators describe stacking it with peptides such as LL-37 for active infections, or with BPC-157 and TB-500 around surgery or injury, though these combinations are anecdotal rather than trial-tested.

What sets thymosin alpha-1 apart is that it behaves like a modulator, often described as a thermostat rather than a gas pedal, nudging a weak immune response up or an overactive one down toward balance depending on what the local tissue needs. It acts largely on dendritic cells and works through two opposing arms at once. One arm signals through toll-like receptor 2, driving NF-kB and a TH1 response that matures dendritic cells and activates natural killer cells for antiviral and anti-tumor defense. The other arm signals through toll-like receptor 9, producing type 1 interferons that switch on the enzyme IDO, which depletes tryptophan and generates regulatory T cells that calm the response. Because both arms fire simultaneously, the surrounding environment decides which dominates, and a 2020 mouse study showed the same molecule boosting anti-tumor immunity at a tumor site while calming inflammation in the gut of the same animal.

Thymosin alpha-1 is almost always given by subcutaneous injection, typically into abdominal fat with a fine insulin needle, and it comes as a lyophilized powder that is reconstituted with bacteriostatic or sterile water. The clinical standard across most trials is around 1.6 mg twice weekly, a figure originally derived from roughly 900 micrograms per square meter of body surface area, with frequency rather than dose adjusted for different goals. Because its half-life in the blood is short, under about three hours, it is not felt acutely and its effect accumulates gradually over weeks as immune cells are retrained. Reported protocols describe general immune blocks of four to eight weeks, with chronic infection or oncology support running for many months. Oral and intranasal forms are marketed by some vendors, but sources describe injection as the route with actual supporting data.

Thymosin alpha-1 is unusually well documented for a peptide, with the synthetic form studied in more than 11,000 subjects across over 30 clinical trials plus decades of post-marketing use abroad. The strongest human data is in hepatitis B, where a majority of treated patients cleared or converted the surface antigen, and vaccine-enhancement trials in elderly men showed higher antibody responses and lower influenza incidence. Cancer data is newer and framed as immune priming rather than direct tumor killing, with 2025 and 2026 studies suggesting better outcomes when it is added to chemoradiotherapy or immunotherapy. Against this, the largest randomized trial to date, the TESTS phase 3 sepsis study of 1,089 adults reported in January 2025, did not reduce mortality overall, though subgroup signals suggested benefit in older and diabetic patients and possible harm in those under 60. Enthusiasm around long COVID, autoimmune conditions, and cystic fibrosis rests mostly on mechanism or small studies, and a high-profile 2017 cystic fibrosis claim was later corrected after independent labs could not reproduce it.

As of this writing, thymosin alpha-1 is not FDA approved in the United States, so domestically it circulates as a research chemical rather than a prescription drug. It holds FDA orphan drug designations for melanoma, hepatocellular carcinoma, and hepatitis B, but designations are not approvals. The regulatory picture has been shifting, with the FDA removing it from a restricted category in September 2024, an advisory committee voting in December 2024 against adding it to the approved compounding list, and further review expected in 2026, so the status can change quickly. Internationally the situation is very different, as the thymalfasin form is approved in roughly 37 countries under the brand name Zadaxin. One safety-relevant caution repeatedly raised is combining it with checkpoint inhibitor cancer drugs, since a case report documented severe multi-system reactions when the two forms of immune activation stacked, making oncologist involvement important for anyone in cancer treatment.